Nadine Beauger , Ph.D., MBA, Senior Director – Therapeutic Accelerator, Boston Children’s Hospital, Technology & Innovation Development Office (TIDO)

Dr. Beauger recently joined TIDO as Senior Director of the newly launched Therapeutic Accelerator. She will play an integral role in driving hospital innovations to advance our mission of improving the health and well-being of children around the world. She will oversee critical project funding initiatives and strategic alliances with industry partners. Her leadership will also extend to managing other key commercialization efforts that align with TIDO’s commitment to transforming cutting-edge research into tangible solutions for pediatric patients.

Dr. Beauger is a Senior Executive with more than 25 years of proven expertise in building and delivering high value drug discovery assets in life sciences including corporate and business strategy, technology identification and transfer, project management, venture capital, intellectual property, and drug discovery research.

She was previously the President and CEO of IRICoR, a Centre of Excellence in Commercialization and Research specializing in drug discovery, based at IRIC/University of Montreal. She raised 40M$ from public and private sources to lead her organization to expand its project portfolio and funding beyond Quebec, to the rest of Canada. Under her leadership, IRICoR entered into multi-year multi-M$ R&D partnerships and license agreements with international pharma companies (AbbVie, Medigene, ONO Pharmaceuticals, IPSEN Pharma among others) for further development of portfolio projects and contributed to the creation of spin-offs such as clinical-stage cell expansion leader ExCellThera, cancer stem cell and epigenomics innovative platform boutique RejuvenRx and immunotherapeutic target engine Epitopea. Before this appointment, Dr. Beauger was Vice-President – Scientific Liaison at that same organization that she joined in 2009. She was instrumental at building IRICoR’s project portfolio and related intellectual property (IP) practice and strategy, which have led to successful licensing agreements and partnerships with global pharma and VC partners.

She brought to IRICoR over 10 years of experience in technology assessment and transfer, venture capital, IP and project portfolio management, due diligence, and research with thorough experience in both the private and the academic sectors, namely at Robic, a Montreal-based IP boutique; VantagePoint Capital Partners (fka VantagePoint Venture Partners), a leading California-headquartered venture capital firm; and Paladin Labs Inc, a top specialty pharmaceutical company based in Montreal.

She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), an M.Sc. in Cellular Biopathology from Université de Montréal, a B.Sc. in Anatomy from McGill University and an MBA degree from HEC Montréal (Excellence Studentship Award and Best Speaker Award).

Nadine sits on different Boards of directors and committees (private and public organizations). She is regularly invited by both the Quebec provincial and Canadian federal governments to share her views on topics relating to commercialization of innovation in life sciences.